Sterne Kessler’s IP Year in Review Reports provide a comprehensive analysis of key developments, trends, and cases that shaped the intellectual property landscape over the past year. These reports offer valuable insights covering artificial intelligence and IP, design patents, appeals at the federal circuit, post-grant proceedings at the Patent Trial and Appeal Board (PTAB), and matters before the U.S. International Trade Commission (ITC).

In the rapidly evolving world of artificial intelligence (AI), safeguarding your intellectual property (IP) is critical. As a market and thought leader in the technology sector, Sterne Kessler helps clients develop comprehensive IP solutions that protect innovation, foster growth, and maximize value. Whether you are an emerging startup company or a well-established technology pioneer, we are committed to helping you harness the full potential of AI technology.

At Sterne Kessler, we know what it takes to win across any venue in pharmaceutical IP litigation. Our award-winning team has a deep bench of experienced litigators representing biosimilars as well as generic and specialty brand pharmaceutical companies in high-profile patent litigation, including blockbuster Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters.

With one of the nation’s top ITC practices, Sterne Kessler offers unrivaled experience, comprehensive litigation strategy, and the legal and technical know-how to achieve the best possible results. In the last five years, Sterne Kessler has handled more cases at the ITC than 90% of firms appearing before the Commission.

For nearly four decades, Sterne Kessler has been at the forefront of design patents, consistently delivering successful outcomes for clients in securing and defending their design rights. We develop effective, comprehensive IP programs to protect some of the most iconic product designs in the world and to eliminate knock-offs in the marketplace.